Skip to main content
Premium Trial:

Request an Annual Quote

Sophia Genetics Obtains CE-IVD Mark for Bioinformatics Pipeline

NEW YORK (GenomeWeb) – Sophia Genetics said today that it has obtained the CE-IVD Mark for its next-generation sequencing bioinformatics pipeline for routine genetic testing.

The CE-IVD Mark enables the Lausanne, Switzerland-based firm to offer the pipeline in all markets accepting the CE mark in Europe, Latin America, Middle East, Africa, and Asia. Sophia said that it will also seek to obtain the CE Mark for all of the genetic tests it supports.

"The barrier to wider adoption of next-generation sequencing data for the routine genetic testing of patients has historically been the challenge associated with analyzing data," Jurgi Camblong, CEO of Sophia Genetics, said in a statement. "We have designed solutions to address even the most difficult data analysis problems that existing bioinformatics software programs are not able to solve, making NGS genetic testing much simpler, faster, and easier for our lab customers."

Sophia also noted that it recently received ISO 13485 accreditation, which covers requirements for quality management systems. The firm said that clinical labs using its service " gain access to quality assurance expertise, facilitating both cost-saving and time-efficient filing for ISO 15189 accreditation and compliance with the new CE-IVD Directive."

The Scan

Octopus Brain Complexity Linked to MicroRNA Expansions

Investigators saw microRNA gene expansions coinciding with complex brains when they analyzed certain cephalopod transcriptomes, as they report in Science Advances.

Study Tracks Outcomes in Children Born to Zika Virus-Infected Mothers

By following pregnancy outcomes for women with RT-PCR-confirmed Zika virus infections, researchers saw in Lancet Regional Health congenital abnormalities in roughly one-third of live-born children.

Team Presents Benchmark Study of RNA Classification Tools

With more than 135 transcriptomic datasets, researchers tested two dozen coding and non-coding RNA classification tools, establishing a set of potentially misclassified transcripts, as they report in Nucleic Acids Research.

Breast Cancer Risk Related to Pathogenic BRCA1 Mutation May Be Modified by Repeats

Several variable number tandem repeats appear to impact breast cancer risk and age at diagnosis in almost 350 individuals carrying a risky Ashkenazi Jewish BRCA1 founder mutation.